News und Analysen
Natera Q2 Earnings Call Highlights
Natera (NASDAQ:NTRA) reported second-quarter 2026 revenue of approximately $753 million, up about 38% from a year earlier, as record testing volumes and
Intellia Therapeutics Q2 Earnings Call Highlights
Intellia Therapeutics (NASDAQ:NTLA) said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase
Microvision Q2 Earnings Call Highlights
Key Points
- Interested in Microvision, Inc.? Here are five stocks we like better.
- Revenue and margins improved: MicroVision reported Q2 2026 revenue of $1.5 million, up $1.3 million year over
iRhythm Technologies Q2 Earnings Call Highlights
Key Points
- Interested in iRhythm Technologies? Here are five stocks we like better.
- Strong Q2 performance: Revenue rose 20.1% year over year to $224.2 million, while adjusted EBITDA reached
Inogen Q2 Earnings Call Highlights
Key Points
- Interested in Inogen, Inc? Here are five stocks we like better.
- Second-quarter revenue rose 3% to $95.1 million, with international sales up 15% and new products helping offset a 2%
Cytokinetics Q2 Earnings Call Highlights
Key Points
- Interested in Cytokinetics, Incorporated? Here are five stocks we like better.
- MYQORZO’s U.S. launch is gaining traction: The drug reached 1,500 dispensed patients and more than 700
CytomX Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in CytomX Therapeutics, Inc.? Here are five stocks we like better.
- Varseta-M remains CytomX’s primary focus: The Phase I monotherapy study has enrolled 113 patients, with
Corvus Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Corvus Pharmaceuticals, Inc.? Here are five stocks we like better.
- Corvus reported a wider Q2 loss as research and development spending rose to $16 million for
Ardelyx Q2 Earnings Call Highlights
Key Points
- Interested in Ardelyx, Inc.? Here are five stocks we like better.
- Second-quarter product revenue reached a record $118 million, up 31% year over year, but Ardelyx lowered its 2026
Ligand Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Ligand Pharmaceuticals Incorporated? Here are five stocks we like better.
- Q2 results strengthened: Revenue rose 34% year over year to $64 million, royalty revenue
Insmed Q2 Earnings Call Highlights
Key Points
- Interested in Insmed, Inc.? Here are five stocks we like better.
- BRINSUPRI sales accelerated: Second-quarter revenue reached $309.2 million, up 49% sequentially, prompting Insmed to
CareCloud Q2 Earnings Call Highlights
Key Points
- Interested in CareCloud, Inc.? Here are five stocks we like better.
- CareCloud’s Q2 revenue rose 16% to $31.9 million, marking its ninth consecutive quarter of GAAP profitability
Vir Biotechnology Q2 Earnings Call Highlights
Vir Biotechnology (NASDAQ:VIR) reported second-quarter 2026 results alongside updates on its chronic hepatitis delta and oncology programs
Trupanion Q2 Earnings Call Highlights
Trupanion (NASDAQ:TRUP) reported higher second-quarter revenue and adjusted operating income as the pet insurer benefited from increased subscription
Remitly Global Q2 Earnings Call Highlights
Key Points
- Interested in Remitly Global, Inc.? Here are five stocks we like better.
- Strong second-quarter performance: Revenue rose 20% year over year to $495 million, while adjusted EBITDA
Portillo's Q2 Earnings Call Highlights
Key Points
- Interested in Portillo's Inc.? Here are five stocks we like better.
- Second-quarter revenue rose 5.6% to $199 million on new restaurant openings, but same-restaurant sales declined
Pacific Biosciences of California Q2 Earnings Call Highlights
Key Points
- Interested in Pacific Biosciences of California, Inc.? Here are five stocks we like better.
- Leadership and outlook changed: CEO Christian Henry stepped down and was replaced
MannKind Q2 Earnings Call Highlights
Key Points
- Interested in MannKind Corporation? Here are five stocks we like better.
- Second-quarter revenue rose 43% to $109.4 million, driven by commercial products and collaboration revenue
Evolus Q2 Earnings Call Highlights
Key Points
- Interested in Evolus, Inc.? Here are five stocks we like better.
- Strong second-quarter performance: Evolus reported 21% revenue growth to $84.1 million and its third consecutive
Coherus Oncology Q2 Earnings Call Highlights
Key Points
- Interested in Coherus Oncology, Inc.? Here are five stocks we like better.
- Clinical milestones are approaching: Coherus expects formal October data from its fully enrolled
Akebia Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Akebia Therapeutics, Inc.? Here are five stocks we like better.
- Vafseo revenue rose sharply to $21.3 million in Q2 2026, up 34% sequentially and 60% year over year
Geron Q2 Earnings Call Highlights
Key Points
- Interested in Geron Corporation? Here are five stocks we like better.
- Geron reported strong second-quarter performance, with revenue rising 17% year over year to $57.5 million and
Compass Pathways Q2 Earnings Call Highlights
Key Points
- Interested in Compass Pathways PLC Sponsored ADR? Here are five stocks we like better.
- Compass Pathways remains on track to file for FDA approval of COMP360 for treatment-resistant
Aurora Cannabis Q1 Earnings Call Highlights
Key Points
- Interested in Aurora Cannabis Inc.? Here are five stocks we like better.
- International medical cannabis drove growth: Revenue rose to C$67.6 million, with international medical
EQS-News: Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Halbjahres 2026 ein und gibt Teilnahme an internationalen Investorenkonferenzen bekannt
EQS-News: Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Halbjahres 2026 ein und gibt Teilnahme an internationalen Investorenkonferenzen bekannt
